Conventional and genetic evidence on the association between adiposity and CKD

Conventional and genetic evidence on the association between adiposity and CKD

<p><strong>Background </strong>The size of any causal contribution of central and general adiposity to CKD risk and the underlying mechanism of mediation are unknown.</p> <p><strong>Methods</strong> Data from 281,228 UK Biobank participants were used to est...

Bibliografske podrobnosti
Main Authors:	Zhu, P, Herrington, WG, Haynes, R, Emberson, J, Landray, MJ, Sudlow, CLM, Woodward, M, Baigent, C, Lewington, S, Staplin, N
Format:	Journal article
Jezik:	English
Izdano:	American Society of Nephrology 2020

Podobne knjige/članki

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
od: Zhu, P, et al.
Izdano: (2020)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
od: Zhu, P, et al.
Izdano: (2020)

Evidence for the prevention and treatment of stroke in dialysis patients
od: Herrington, W, et al.
Izdano: (2014)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
od: Lamprea-Montealegre, J, et al.
Izdano: (2019)

Impact of CKD on household income
od: Morton, R, et al.
Izdano: (2017)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
od: Haynes, R, et al.
Izdano: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
od: Haynes, R, et al.
Izdano: (2014)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
od: Staplin, N, et al.
Izdano: (2022)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
od: Staplin, N, et al.
Izdano: (2015)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
od: Staplin, N, et al.
Izdano: (2016)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
od: Emberson, J, et al.
Izdano: (2016)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
od: Herrington, W, et al.
Izdano: (2016)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
od: Herrington, WG, et al.
Izdano: (2023)

Bioimpedance in CKD: an untapped resource?
od: Mayne, KJ, et al.
Izdano: (2022)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
od: Haynes, R, et al.
Izdano: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
od: Herrington, W, et al.
Izdano: (2022)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
od: Judge, PK, et al.
Izdano: (2023)

Serum free light chains and the risk of ESRD and death in CKD.
od: Haynes, R, et al.
Izdano: (2011)

Serum free light chains and the risk of ESRD and death in CKD
od: Haynes, R, et al.
Izdano: (2011)

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality
od: Zhu, D, et al.
Izdano: (2024)

In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
od: Mayne, KJ, et al.
Izdano: (2022)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
od: Storey, B, et al.
Izdano: (2018)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
od: Staplin, N, et al.
Izdano: (2021)

Allocated but not treated: the silent 16% – Authors' reply
od: Horby, P, et al.
Izdano: (2022)

Impact of CKD on Household Income
od: Rachael L. Morton, et al.
Izdano: (2018-05-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
od: Storey, B, et al.
Izdano: (2017)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
od: Fletcher, RA, et al.
Izdano: (2024)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
od: Mayne, KM, et al.
Izdano: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
od: Mayne, K, et al.
Izdano: (2024)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
od: Herrington, W, et al.
Izdano: (2015)

In CKD, the kidney failure risk equation predicted 2-y risk for ESKD better than eGFR alone
od: Aguilar-Ramirez, D, et al.
Izdano: (2022)

Accelerometer-measured physical activity and functional behaviours among people on dialysis
od: Nawab, KA, et al.
Izdano: (2020)

Haemodialysis, blood pressure and risk: At the limit of non-randomized evidence
od: Ng, SYA, et al.
Izdano: (2020)

Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults
od: Aguilar-Ramirez, D, et al.
Izdano: (2022)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
od: Herrington, W, et al.
Izdano: (2014)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
od: Mayne, K, et al.
Izdano: (2023)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
od: Mihaylova, B, et al.
Izdano: (2019)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
od: Herrington, W, et al.
Izdano: (2018)

Kidney disease trials for the 21st century: innovations in design and conduct
od: Herrington, W, et al.
Izdano: (2019)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
od: Emberson, JR, et al.
Izdano: (2010)